FULCRUM THERAPEUTICS

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024

13 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference

12 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET

06 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Oct 2024 16:30:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13 Sep 2024 16:30:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

12 Sep 2024 06:55:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate in Upcoming September Conferences

27 Aug 2024 16:05:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

23 Aug 2024 16:30:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer

19 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09 Aug 2024 16:30:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024

31 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ET

24 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress

12 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate in the Goldman Sachs’ 45th Annual Global Healthcare Conference

06 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024

13 May 2024 07:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy

13 May 2024 06:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate in Upcoming May Conferences

09 May 2024 08:00:01 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology

08 May 2024 08:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET

06 May 2024 08:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium

28 Mar 2024 16:05:00 By Nasdaq GlobeNewswire